BIO-key Q2 Loss Narrows 51% on 13% Revenue Growth; $2.5M Warrant Exercise Boosts Cash
BKYI is trading near its 52-week low of $3.1 (3.2% below the low).
Summary
BIO-key reported Q2 revenue up 13% and net loss down 51%, while a $2.5M warrant exercise boosted cash to over $4.5M.
Key Events · Earnings and Guidance · BKYI
-
Q2 Revenue Up 13%
Total revenues increased to $1.92M from $1.70M in Q2'25, driven by a 53% jump in license fee revenue to $1.23M.
-
Net Loss Cut 51%
Net loss improved to $577K ($0.56/share) from $1.17M ($2.01/share) a year ago, reflecting higher gross profit and 5% lower operating expenses.
-
Gross Margin Expands to 87%
Gross margin rose from 73% to 87% due to higher-margin license fees and sales of fully-reserved hardware inventory.
-
$2.5M Warrant Exercise
Raised $2.5M via exercise of 618,334 warrants at $4.06/share, plus issuance of 1,236,668 new warrants at the same strike, lifting cash to over $4.5M.
Analysis · BKYI · Technology
BIO-key's Q2 results show meaningful improvement: revenue up 13% to $1.9M, gross margin expanded to 87%, and net loss cut by more than half to $577K. The company also raised $2.5M through a warrant inducement at $4.06 per share, lifting cash to over $4.5M. While the loss remains, the trajectory is positive and the financing removes near-term liquidity pressure. The stock trades near its 52-week low, so this operational progress and strengthened balance sheet could support a re-rating.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.5% of the 1626 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BKYI was trading at $3.00 on NASDAQ in the Technology sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $3.10 to $19.70. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.